Workflow
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
GlobeNewswire· 2025-05-23 00:57
SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced the pricing of its previously announced underwritten public offering of 2,222,222 shares of its common stock at a public offering price of $9.00 per share. In addition, Gyre has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 333,333 shares of its common stock at the p ...
Algernon Closes NoBrainer Imaging Centers, Inc. Acquisition
GlobeNewswire· 2025-05-23 00:50
Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinical stage drug development company, is pleased to announce it has closed the acquisition to acquire 100% of the issued and outstanding shares of NoBrainer Imaging Centers, Inc. VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinical stage drug developm ...
CECOCECO to Unveil ArtMorph Innovation at AIA Conference on Architecture & Design 2025
GlobeNewswire· 2025-05-23 00:45
BOSTON, May 22, 2025 (GLOBE NEWSWIRE) -- CECOCECO, a leading innovator in the lighting and display industry, is excited to announce its participation in the AIA Conference on Architecture & Design 2025, taking place from June 4-7 in Boston. At Booth #1119, CECOCECO will present the latest edition of ArtMorph—an innovative luminous wall panel that seamlessly blends LED display technology with textures. Hosted by the American Institute of Architects (AIA), the conference is one of the industry's most influent ...
Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025
GlobeNewswire· 2025-05-23 00:15
ROCKVILLE, Md. and SUZHOU, China, May 22, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, today announced that new clinical data from two ongoing investigational studies evaluating lisaftoclax in various blood cancers and alrizomadlin in solid tumors will be presented during an oral presentation and poster presentation, respectively, at the 2025 American Society of Clinical Oncology (ASCO) Annual ...
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages UnitedHealth Group Incorporated Investors to Secure Counsel Before Important Deadline in Securities Class Action Commenced by the Firm– UNH
GlobeNewswire News Room· 2025-05-23 00:14
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of UnitedHealth Group Incorporated (NYSE: UNH) between December 3, 2024 and May 12, 2025, both dates inclusive (the “Class Period”), of the important July 7, 2025 lead plaintiff deadline in the securities class action commenced by the firm. SO WHAT: If you purchased UnitedHealth securities during the Class Period you may be entitled to compensation without payment of any out o ...
CARsgen's Satri-cel Abstract Available on ASCO Website
Prnewswire· 2025-05-23 00:00
SHANGHAI, May 22, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that an abstract of the research results of the confirmatory Phase II clinical trial of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against protein Claudin18.2) for advanced gastric/gastroesophageal junction cancer (G/GEJC) in China (CT041-ST-01, NCT04581473) is available on the American S ...
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting
GlobeNewswire· 2025-05-23 00:00
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new data from several studies of compounds discovered by HUTCHMED including savolitinib, ranosidenib, fruquintinib and surufatinib, will be presented at the American Society of Clinical Oncology (“ASCO”) Annual Meeting taking place on May 30 – June 3, 2025 in Chicago, USA. Results from the SACHI China Phase III study of savolitinib in combinat ...
Entertainment Without Borders: AI-Media and Lightning International Join Forces to Make FAST Channels Accessible to Everyone
GlobeNewswire· 2025-05-22 23:45
AI-Media and Lightning International Partnership AI-Media and Lightning International Join Forces to Make FAST Channels Accessible to Everyone SYDNEY and HONG KONG, May 22, 2025 (GLOBE NEWSWIRE) -- AI-Media Technologies Limited ("AI-Media"), a global leader in live captioning and translation solutions, has entered a groundbreaking partnership with Lightning International ("Lightning"), the leading distributor of Free Ad-Supported Television (FAST) channels. This collaboration aims to break down barriers ...
Thermon's Backlog Rises on LNG Growth
The Motley Fool· 2025-05-22 23:37
Thermon Group (THR -0.89%) delivered its fiscal 2025 fourth-quarter results on May 22, reporting 5% year-over-year revenue growth to $134.1 million, an adjusted EBITDA margin of 22.7%, and record annual free cash flow of $53 million. Management at the industrial process heating specialist highlighted a 29% year-over-year backlog increase as of March 31 (the quarter's end), strategic expansion into high-growth markets, and outlined the tariff headwinds it expects for fiscal 2026, as well as its plans for rig ...
Amazon shareholders reject proposal to split CEO and chair roles
CNBC· 2025-05-22 23:22
Amazon CEO Andy Jassy speaks during an unveiling event in New York on Feb. 26, 2025.Amazon shareholders rejected a proposal to adopt a policy that would require the company's CEO and board chair roles to remain separate.Vote totals disclosed in a filing Thursday show about 82% of shareholders rejected the proposal. The independent proposal was submitted alongside seven others at Amazon's annual meeting on Wednesday. Each of the independent proposals were rejected.Amazon split the roles of CEO and board chai ...